Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens

Vaccine

Volumn 25, Issue 47, 2007, Pages 7984-7993

  Uddowla, Sabena ^a   Freytag, Lucy C ^a   Clements, John D ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Adjuvants; Plague; Vaccines; Y. pestis F1 V

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; BACTERIAL ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; ESCHERICHIA COLI ENTEROTOXIN; MPL; PHOSPHORYL LIPID A; PLAGUE VACCINE; RECOMBINANT YERSINIA PESTIS DERIVED FUSION PROTEIN; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BRONCHOALVEOLAR LAVAGE; DRUG ADMINISTRATION ROUTES; FEMALE; IMMUNIZATION; MICE; PLAGUE; PLAGUE VACCINE; RECOMBINANT PROTEINS;

EID: 35448963924     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.030     Document Type: Article

References (20)

1. Clements J.D., Hartzog N.M., and Lyon F.L. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6 3 (1988) 269-277
2. Elson C.O. Cholera toxin and its subunits as potential oral adjuvants. Curr Top Microbiol Immunol 146 (1989) 29-33
3. Lycke N., Tsuji T., and Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 22 9 (1992) 2277-2281
4. Xu-Amano J., Kiyono H., Jackson R.J., Staats H.F., Fujihashi K., Burrows P.D., et al. Helper T-cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 178 4 (1993) 1309-1320
5. Yamamoto M., Vancott J.L., Okahashi N., Marinaro M., Kiyono H., Fujihashi K., et al. The role of Th1 and Th2 cells for mucosal IgA responses. Ann N Y Acad Sci 778 (1996) 64-71
6. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
7. Carozzi S., Salit M., Cantaluppi A., Nasini M.G., Barocci S., Cantarella S., et al. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol 27 8 (1989) 1748-1753
8. Henricson B.E., Manthey C.L., Perera P.Y., Hamilton T.A., and Vogel S.N. Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A. Infect Immun 61 6 (1993) 2325-2333
9. Myers K.R., Beining P., Betts M., Snippe H., Inman J., and Golding B. Monophosphoryl lipid A behaves as a T-cell-independent Type 1 carrier for hapten-specific antibody responses in mice. Infect Immun 63 1 (1995) 168-174
10. Glynn A., Freytag L.C., and Clements J.D. Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens. Vaccine 23 16 (2005) 1957-1965
11. Heath D.G., Anderson Jr. G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 11-12 (1998) 1131-1137
12. Jarrett C.O., Sebbane F., Adamovicz J.J., Andrews G.P., and Hinnebusch B.J. Flea-borne transmission model to evaluate vaccine efficacy against naturally acquired bubonic plague. Infect Immun 72 4 (2004) 2052-2056
13. Glynn A., Roy C.J., Powell B.S., Adamovicz J.J., Freytag L.C., and Clements J.D. Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun 73 8 (2005) 5256-5261
14. Cheng E., Cardenas-Freytag L., and Clements J.D. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18 1-2 (1999) 38-49
15. Goodin J.L., Nellis D.F., Powell B.S., Vyas V.V., Enama J.T., Wang L.C., et al. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Exp Purif 53 1 (2007) 63-79
16. Brewer J.M. How do aluminium adjuvants work?. Immunol Lett 102 1 (2006) 10-15
17. Ulanova M., Tarkowski A., Hahn-Zoric M., and Hanson L.A. The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69 2 (2001) 1151-1159
18. Freytag L.C., and Clements J.D. Mucosal adjuvants. Vaccine 23 15 (2005) 1804-1813
19. Martin M., Sharpe A., Clements J.D., and Michalek S.M. Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli. J Immunol 169 4 (2002) 1744-1752
20. Baldridge J.R., and Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19 1 (1999) 103-107